author-photo

Madalina Tuluc

Thomas Jefferson University
Thomas Jefferson University Hospital

85

Papers

1210

Citations

Citation Trend

Filter By

Papers (61) Sort By

Journal Conference Others

Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.

2021 Journal of Medical Case Reports
Show All
- Source
- Cite
- Save
Citations (0)
861MO Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
How Increased Nodal Metastasis and Recurrence in Cribriform Adenocarcinoma relate to Polymorphous Adenocarcinoma and Survival: a Systematic Review

2021 Journal of Oral and Maxillofacial Surgery
Show All
- Source
- Cite
- Save
Citations (0)
Uncontrolled Diabetic with a Nonpainful, Exophytic, Purulent Mandibular Mass

2020 Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology
Show All
- Source
- Cite
- Save
Citations (0)
Pathologist Opinions about EPIC Beaker AP: a Multi-Institutional Survey of Early Adopters.

2020 Journal of Medical Systems
Show All
- Source
- Cite
- Save
Citations (0)
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

2020 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Multi-organ sarcoidosis like reaction mimics metastatic disease in a microsatellite instability-high melanoma patient treated with checkpoint inhibitors

2020 Human Pathology: Case Reports
Show All
- Source
- Cite
- Save
Citations (0)
968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)